OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Human Metabolome Technologies's OCF Yield % or its related term are showing as below:
TSE:6090'
s OCF Yield % Range Over the Past 10 Years
Min: 11.53 Med: 0 Max: 11.53
Current: 11.53
During the past 12 years, the highest OCF Yield % of Human Metabolome Technologies was 11.53%. The lowest was 11.53%. And the median was %.
TSE:6090's OCF Yield % is ranked better than 89.2% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.04
vs TSE:6090: 11.53
Human Metabolome Technologies OCF Yield % Explanation
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Human Metabolome Technologies OCF Yield % Related Terms
Human Metabolome Technologies OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6090 vs TMO, DHR, IDXX: OCF Yield % Comparison
For the Diagnostics & Research subindustry, Human Metabolome Technologies's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies OCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies (TSE:6090) has a OCF Yield % of 11.53 as of Jul. 12, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Human Metabolome Technologies and its competitors. Over the past decade, Human Metabolome Technologies' OCF Yield % has ranged from 11.53 to 11.53. According to the industry distribution chart, Human Metabolome Technologies ranks #23 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 10.8%.
Is Human Metabolome Technologies' OCF Yield % too high?
Human Metabolome Technologies' current OCF Yield % is 11.53. Over the past 10 years, this metric has ranged from a low of 11.53 to a high of 11.53. The Medical Diagnostics & Research industry median OCF Yield % is 1.04. Human Metabolome Technologies' value of 11.53 is 1008.7% above this industry median. Based on the distribution chart, Human Metabolome Technologies ranks #23 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Human Metabolome Technologies has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' OCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #23 out of 213 companies for OCF Yield %. This places Human Metabolome Technologies in the top 11% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 1.04. Human Metabolome Technologies' value of 11.53 is 1008.7% above this benchmark. Historically, Human Metabolome Technologies' own OCF Yield % has ranged from 11.53 to 11.53 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Diagnostics & Research company?
The median OCF Yield % among Medical Diagnostics & Research companies is 1.04, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Human Metabolome Technologies's current OCF Yield % of 11.53 is 1008.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Human Metabolome Technologies and its competitors. For the Medical Diagnostics & Research industry, the median OCF Yield % is 1.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Human Metabolome Technologies's current OCF Yield % is 11.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Overvalued. The stock's GF Value™ is 円529.55, compared to a current price of 円598.00 — trading 12.9% above its estimated fair value. The current OCF Yield % is 11.53 and 1008.7% above the Medical Diagnostics & Research industry median of 1.04. Human Metabolome Technologies' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current OCF Yield % is 11.53 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be overvalued.
The current stock price of 円598.00 is trading 12.9% above its estimated GF Value™ of 円529.55.
GuruFocus considers Human Metabolome Technologies to be Modestly Overvalued.
Key valuation signals for TSE:6090:
OCF Yield %: 11.53
GF Value™: 円529.55 vs. price of 円598.00 (12.9% above fair value)
Industry Position: 1008.7% above the Medical Diagnostics & Research median (#23 of 213)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Human Metabolome Technologies Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
